Advanced search
Publication Cover
Pharmacogenomics Volume 10, 2009 - Issue 6
Submit an article Journal homepage
276
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Impact of Apolipoprotein A5 Variants on Statin Treatment Efficacy

Jaroslav A Hubacek1 Cardiovascular Research Centre, IKEM-DEM-LMG, Videnska 1958/9, 140 21, Prague 4, Czech Republic. [email protected];2 Institute for Clinical and Experimental Medicine, Prague, Czech Republic;3 University & General University Hospital in Prague, Czech Republic;4 South Bohemia University, Ceske Budejovice, Czech RepublicView further author information
,
Vera Adamkova2 Institute for Clinical and Experimental Medicine, Prague, Czech Republic;4 South Bohemia University, Ceske Budejovice, Czech RepublicView further author information
,
Martina Prusikova3 University & General University Hospital in Prague, Czech RepublicView further author information
,
Michaela Snejdrlova3 University & General University Hospital in Prague, Czech RepublicView further author information
,
Katerina Hirschfeldova3 University & General University Hospital in Prague, Czech RepublicView further author information
,
Vera Lanska2 Institute for Clinical and Experimental Medicine, Prague, Czech RepublicView further author information
,
Richard Ceska3 University & General University Hospital in Prague, Czech RepublicView further author information
&
Michal Vrablik3 University & General University Hospital in Prague, Czech RepublicView further author information
 show all
Pages 945-950 | Published online: 17 Jun 2009

Bibliography

  • Libby P : The forgotten majority: unfinished business in cardiovascular risk reduction.J. Am. Coll. Cardiol.46(7) , 1225–1228 (2005).
  • Schmitz G , LangmannT: Pharmacogenomics of cholesterol-lowering therapy.Vascular Pharm.44(2) , 75–89 (2006).
  • Mangravite LM , KraussRM: Pharmacogenetics of statin response.Curr. Opin. Lipidol.18(4) , 409–419 (2007).
  • Pennacchio LA , OlivierM, HubacekJA et al.: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing.Science294(5540) , 169–173 (2001).
  • Hubacek JA , SkodovaZ, LanskaV, AdamkovaV: Apolipoprotein A-V variant (T-1131>C) affects plasma levels of non-high-density lipoprotein cholesterol in Caucasians.Exp. Clin. Cardiol.13(3) , 129–132 (2008).
  • Lai CQ , DemissieS, CupplesLA et al.: Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study.J. Lipid Res.45(11) , 2096–2105 (2004).
  • Hubacek JA : Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants.Clin. Chem. Lab. Med.43(9) , 897–902 (2005).
  • Calandra S , Priore Oliva C, Tarugi P, Bertolini S: APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr. Opin. Lipidol.17(2) , 122–127 (2006).
  • Hubáček JA , ŠkodováZ, AdámkováV, LánskáV, PoledneR: The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction.Clin. Genet.65(2) , 126–130 (2004).
  • Szalai C , KeszeiM, DubaJ et al:. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis173(1) , 109–114 (2004).
  • Tai ES , OrdovasJM: Clinical significance of apolipoprotein A5.Curr. Opin. Lipidol.19(4) , 349–354 (2008).
  • Dorfmeister B , ZengWW, DichlbergerA et al.: Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding.Arterioscler. Thromb. Vasc. Biol.28(10) , 1866–1871 (2008).
  • Hubacek JA , ŠkodováZ, AdámkováV, LánskáV, PithaJ: APOA5 variant Ser19Trp influences a decrease of the total cholesterol in a males 8 years cohort.Clin. Biochem.39(2) , 133–136 (2006).
  • Hubacek JA , BohuslavovaR, ŠkodováZ, PithaJ, BobkovaD, PoledneR: Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to dietary change.Clin. Chem. Lab. Med.45(3) , 316–320 (2007).
  • Lai CQ , CorellaD, DemissieS et al.: Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: The Framingham Heart Study.Circulation113(17) , 2076–2070 (2006).
  • Lai CQ , ArnettDK, CorellaD et al.: Fenofibrate efect on triglyceride and postprandial response of apolipoprotein A5 variants. The GOLDN study.Arterioscler. Thromb. Vasc. Biol.27(6) , 1417–1425 (2007).
  • Hubacek JA , SkodovaZ, AdamkovaV, LanskaV, PoledneR: Sex-specific effect of APOAV variant (Val153>Met) on plasma levels of high-density lipoprotein cholesterol.Metabolism54(12) , 1632–1635 (2005).
  • Dallinga-Thie GM , van Tol A, Hattori H et al.: Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia49(7) , 1505–1511 (2006).
  • Talmud PJ , CooperJA, HattoriH, MillerIP, MillerGJ, HumphriesSE: APOA5 genotype, plasma apolipoprotein AV and triglyceride levels and the prospective risk of Type 2 diabetes: results from the Northwick Park Hearth Study II.Diabetologia49(10) , 2337–2340 (2006).
  • O‘Brien PJ , AlbornWE, SloanJH et al.: The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins.Clin. Chem.51(2) , 351–359 (2005).
  • Bai L , YhaoS, HuangX, YhangQ: Upregulating APOAV expression by statins via PPAR-α activated pathway possibly contributes to their triglyceride-lowering effect.Bioscience Hypotheses1(6) , 292–294 (2008).
  • Nieminen T , KähönenM, ViiriLE, GrönroosP, LehtimäkiT: Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease.Pharmacogenomics9(10) , 1475–1486 (2008).
  • Novembre J , JohnsonT, BrycK et al.: Genes mirror geography within Europe.Nature456(6) , 98–101 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.